We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Aushon Launches New CiraplexTM ULTRA Ultrasensitive Assays
Product News

Aushon Launches New CiraplexTM ULTRA Ultrasensitive Assays

Aushon Launches New CiraplexTM ULTRA Ultrasensitive Assays
Product News

Aushon Launches New CiraplexTM ULTRA Ultrasensitive Assays


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Aushon Launches New CiraplexTM ULTRA Ultrasensitive Assays"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Kit NEW 2.jpeg

Aushon BioSystems has announced the launch of CiraplexTM ULTRA Ultrasensitive Assays with multiplexing capabilities. 

“We are excited about the recent collaboration with Pacific Biomarkers and believe the comparative results presented today clearly shows the superior performance characteristics of our new CiraplexTM ULTRA product line”, said Susan Vogt, CEO of Aushon. “We are confident that our CiraTM platform is the most intuitive and easy-to-use ultrasensitive multiplex immunoassay platform on the market today.” 

CiraplexTM ULTRA Ultrasensitive Assays with femtogram/ml (fg/ml) levels of detection address multiple biomarkers in a wide range of therapeutic areas. These kits offer enhanced sensitivity and an extended dynamic range providing quantification below standard. As well, intuitive CiraTM software streamlines the data management process providing exceptional data control. 

“Providing high performance multiplex immunoassays across a wide range of therapeutic areas is the goal of the CiraTM platform”, said Scott Van Arsdell, Ph.D., Vice President, Immunoassay Technology. “Our focus has been to create high sensitivity assays requiring less sample consumption while detecting very subtle differences in levels of low expression proteins.” 

Advertisement